Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
Key findings from prospective evaluation of 200 prenatal samples:
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq:BNGO) today announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping (OGM) to a combined workflow of chromosomal microarray analysis (CMA) and karyotyping (KT). The study highlighted OGM’s high analytical concordance with the combined workflow of CMA and KT, and its ability to detect novel pathogenic structural variants (SVs) missed by those methods. The study also highlighted OGM’s potential to provide additional information about SVs and copy number variants (CNVs) compared to CMA and KT.
Related news for (BNGO)
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/10/25 03:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/10/25 02:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/10/25 01:00 PM
- Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing